Zacks
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
📈
AI Sentiment
Highly Positive
9/10
- Home
- EW
as of 12-29-2025 3:38pm EST
$86.99
+$0.12
+0.14%
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 45.5B | IPO Year: | 2000 |
| Target Price: | $95.83 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.33 | EPS Growth: | -66.20 |
| 52 Week Low/High: | $65.94 - $87.89 | Next Earning Date: | 02-10-2026 |
| Revenue: | $5,883,800,000 | Revenue Growth: | 10.60% |
| Revenue Growth (this year): | 14.29% | Revenue Growth (next year): | 9.68% |
AI-Powered EW Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.19%
74.19%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
Chopra Daveen
Sell
CVP, TMTT & Surgical
EW Dec 11, 2025
Avg Cost/Share
$84.38
Shares
2,000
Total Value
$168,750.20
Owned After
32,201
SEC Form 4
BOBO DONALD E JR
Sell
CVP,Strategy/Corp Development
EW Dec 10, 2025
Avg Cost/Share
$83.83
Shares
11,340
Total Value
$950,581.17
Owned After
50,356.371
SEC Form 4
Sell
EW Dec 10, 2025
Avg Cost/Share
$83.45
Shares
3,863
Total Value
$322,367.35
Owned After
8,596.551
SEC Form 4
Ullem Scott B.
Sell
CVP, Chief Financial Officer
EW Dec 9, 2025
Avg Cost/Share
$84.47
Shares
7,700
Total Value
$650,412.07
Owned After
39,898
SEC Form 4
Sell
EW Dec 8, 2025
Avg Cost/Share
$85.21
Shares
21,487
Total Value
$1,831,006.11
Owned After
8,596.551
SEC Form 4
Markowitz Wayne
Sell
CVP, JAPAC
EW Dec 8, 2025
Avg Cost/Share
$86.01
Shares
583
Total Value
$50,143.83
Owned After
17,562.871
SEC Form 4
Ullem Scott B.
Sell
CVP, Chief Financial Officer
EW Nov 10, 2025
Avg Cost/Share
$83.16
Shares
13,000
Total Value
$1,080,093.43
Owned After
39,898
Lippis Daniel J.
Sell
CVP, JAPAC
EW Nov 10, 2025
Avg Cost/Share
$82.55
Shares
1,020
Total Value
$84,196.00
Owned After
22,001.91
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Chopra Daveen | EW | CVP, TMTT & Surgical | Dec 11, 2025 | Sell | $84.38 | 2,000 | $168,750.20 | 32,201 | |
| BOBO DONALD E JR | EW | CVP,Strategy/Corp Development | Dec 10, 2025 | Sell | $83.83 | 11,340 | $950,581.17 | 50,356.371 | |
| Zovighian Bernard J | EW | CEO | Dec 10, 2025 | Sell | $83.45 | 3,863 | $322,367.35 | 8,596.551 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Dec 9, 2025 | Sell | $84.47 | 7,700 | $650,412.07 | 39,898 | |
| Zovighian Bernard J | EW | CEO | Dec 8, 2025 | Sell | $85.21 | 21,487 | $1,831,006.11 | 8,596.551 | |
| Markowitz Wayne | EW | CVP, JAPAC | Dec 8, 2025 | Sell | $86.01 | 583 | $50,143.83 | 17,562.871 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Nov 10, 2025 | Sell | $83.16 | 13,000 | $1,080,093.43 | 39,898 | |
| Lippis Daniel J. | EW | CVP, JAPAC | Nov 10, 2025 | Sell | $82.55 | 1,020 | $84,196.00 | 22,001.91 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
Zacks
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength
📈
AI Sentiment
Highly Positive
8/10
Zacks
The Zacks Analyst Blog Highlights Cardinal Health, Medtronic, Intuitive Surgical and Edwards Lifesciences
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Edwards Lifesciences Says FDA Approves Valve Replacement System
📈
AI Sentiment
Highly Positive
8/10
Business Wire
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
📈
AI Sentiment
Highly Positive
10/10
Compare EW vs Leading Stocks
See how EW stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.